[{"address1": "9350 Kirby Drive", "address2": "Suite 300", "city": "Houston", "state": "TX", "zip": "77054", "country": "United States", "phone": "713 400 6400", "website": "https://markertherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.", "fullTimeEmployees": 8, "maxAge": 86400, "priceHint": 4, "previousClose": 4.49, "open": 4.41, "dayLow": 4.02, "dayHigh": 4.445, "regularMarketPreviousClose": 4.49, "regularMarketOpen": 4.41, "regularMarketDayLow": 4.02, "regularMarketDayHigh": 4.445, "beta": 1.598, "forwardPE": -3.2481203, "volume": 15170, "regularMarketVolume": 15170, "averageVolume": 20104, "averageVolume10days": 47280, "averageDailyVolume10Day": 47280, "bid": 3.12, "ask": 5.23, "bidSize": 200, "askSize": 200, "marketCap": 38530512, "fiftyTwoWeekLow": 2.4, "fiftyTwoWeekHigh": 9.68, "priceToSalesTrailing12Months": 11.602577, "fiftyDayAverage": 4.12, "twoHundredDayAverage": 4.0888, "currency": "USD", "enterpriseValue": 27207062, "profitMargins": -1.705, "floatShares": 6757909, "sharesOutstanding": 8919100, "sharesShort": 50380, "sharesShortPriorMonth": 64427, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0056, "heldPercentInsiders": 0.12204, "heldPercentInstitutions": 0.22782, "shortRatio": 3.98, "shortPercentOfFloat": 0.0078, "impliedSharesOutstanding": 8919100, "bookValue": 1.325, "priceToBook": 3.2603774, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -12213892, "trailingEps": -1.38, "forwardEps": -1.33, "lastSplitFactor": "1:10", "lastSplitDate": 1674777600, "enterpriseToRevenue": 8.193, "52WeekChange": 0.08816123, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "MRKR", "underlyingSymbol": "MRKR", "shortName": "Marker Therapeutics, Inc.", "longName": "Marker Therapeutics, Inc.", "firstTradeDateEpochUtc": 1026826200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f52316f7-d523-378a-bebe-a89c89d1c289", "messageBoardId": "finmb_1725474", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.32, "targetHighPrice": 12.5, "targetLowPrice": 11.0, "targetMeanPrice": 11.75, "targetMedianPrice": 11.75, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 11323428, "totalCashPerShare": 1.27, "quickRatio": 5.719, "currentRatio": 6.117, "totalRevenue": 3320858, "revenuePerShare": 0.375, "returnOnAssets": -0.38127998, "returnOnEquity": -0.88181996, "freeCashflow": -7939947, "operatingCashflow": -14388784, "revenueGrowth": 0.008, "grossMargins": -1.89543, "operatingMargins": -2.04895, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]